Bibliographical noteFunding Information:
AS Kelly has received research funding from Amylin/Eli Lilly and served on a pediatric obesity advisory board (clinical trial design) for Novo Nordisk. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
- glucagon-like peptide-1 receptor agonists
- pediatric obesity